Wealthcare Advisory Partners’s DNA X Inc SONM Stock Holding History

Wealthcare Advisory Partners’s Portfolio SONM Stock Details SONM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-57	Closed	-$5K	–	704
2022 Q3	$5K	Hold	57	–	–	﹤0.01%	600
2022 Q2	$6K	Buy	+57	New	+$6.44K	﹤0.01%	560

Other funds holding SONM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wealthcare Advisory Partners's SONM Position: Q4 2022 in Review

Wealthcare Advisory Partners sold out of DNA X Inc (SONM) in Q4 2022, closing a stake of 57 shares — an estimated $5K sold.

Wealthcare Advisory Partners first reported a position in SONM in Q2 2022 and held it in 2 quarters. The position peaked at $6K in Q2 2022. 13 funds tracked by Wall St. Rank hold SONM as of Q4 2022.

Wealthcare Advisory Partners reported no remaining DNA X Inc position as of Q4 2022 after selling out during the quarter.
Wealthcare Advisory Partners sold 57 DNA X Inc shares in Q4 2022, an estimated $5K.
Wealthcare Advisory Partners first reported a position in DNA X Inc in Q2 2022 and held it in 2 quarters.
Wealthcare Advisory Partners's DNA X Inc position peaked at $6K in Q2 2022.
13 funds tracked by Wall St. Rank held DNA X Inc as of Q4 2022.

Based on Wealthcare Advisory Partners's 13F filing for Q4 2022, filed 13 Feb 2023.